Shares of Defence Therapeutics Inc. (OTCMKTS:DTCFF – Get Free Report) rose 8.4% during mid-day trading on Wednesday . The company traded as high as $0.6827 and last traded at $0.6650. Approximately 78,493 shares traded hands during trading, an increase of 186% from the average daily volume of 27,399 shares. The stock had previously closed at $0.6133.
Defence Therapeutics Stock Performance
The business has a 50 day moving average price of $0.55 and a 200-day moving average price of $0.55.
About Defence Therapeutics
Defence Therapeutics Inc engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments.
Featured Articles
- Five stocks we like better than Defence Therapeutics
- How Investors Can Find the Best Cheap Dividend Stocks
- 3 Stocks Poised to Benefit From Google’s AI Breakthough
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Beyond NVIDIA: 5 Semiconductor Stocks Set to Dominate 2026
- The 3 Best Retail Stocks to Shop for in August
- 3 Stocks You’ll Wish You Bought Before 2026
Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
